Anavex Life Sciences Corp. Common Stock (AVXL)
Stock · NASDAQ · Health Care
$1.31as of 10/16/2026
Price chart
Active signals
AVXL Signal Track Record
How signals performed across all stocks →What AVXL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 31 | -6.2% | 39% | September 29, 2026 |
| Bollinger Band Breakdown | 22 | -0.8% | 45% | September 30, 2026 |
| Bollinger Band Breakout | 21 | -5.4% | 48% | August 3, 2026 |
| 200-Day Moving Average TouchActive now | 12 | 0.0% | 50% | October 9, 2025 |
| Any 20-session window (baseline) | -3.9% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AVXL
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 34
- Website
- www.anavex.com
Fundamentals
- 1-day range
- $1.52$1.61
- Market cap
- $303.96M
- P/E (trailing)
- —
- P/E (forward)
- -2.78
- EPS (trailing)
- $-0.15
- Dividend yield
- —
- Beta
- 1.18
- Avg. volume
- 965.0K
Forecasts
1 analyst ratings
Anavex Life Sciences Corp. Common Stock Competitors
Chosen by industry and closest market cap.
- AVXLAnavex Life Sciences Corp. Common Stock$1.31▼ 11.49%Market cap $303.96MP/E —$1.56$10.38
- NMRANeumora Therapeutics Inc. Common Stock$0.474▲ 11.01%Market cap $303.87MP/E —$0.3154$3.65
- SABSSAB Biotherapeutics Inc. Common Stock$2.53▼ 2.32%Market cap $294.39MP/E 17.75$2.1$5.15
- FATEFate Therapeutics Inc. Common Stock$1.79▼ 7.25%Market cap $290.23MP/E —$0.95$3.23
- IKTInhibikase Therapeutics Inc. Common Stock$1.65▼ 9.84%Market cap $318.20MP/E —$1.33$2.61
- EDITEditas Medicine Inc. Common Stock$2.35▼ 3.69%Market cap $283.93MP/E —$1.66$4.33
- LCTXLineage Cell Therapeutics Inc. Common Stock$0.98▼ 1.01%Market cap $281.71MP/E —$0.8823$2.09
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AVXL Anavex Life Sciences Corp. Common Stock | $303.96M | — | $1.31 | ▼ 11.49% | $1.56$10.38 |
| NMRA Neumora Therapeutics Inc. Common Stock | $303.87M | — | $0.474 | ▲ 11.01% | $0.3154$3.65 |
| SABS SAB Biotherapeutics Inc. Common Stock | $294.39M | 17.75 | $2.53 | ▼ 2.32% | $2.1$5.15 |
| FATE Fate Therapeutics Inc. Common Stock | $290.23M | — | $1.79 | ▼ 7.25% | $0.95$3.23 |
| IKT Inhibikase Therapeutics Inc. Common Stock | $318.20M | — | $1.65 | ▼ 9.84% | $1.33$2.61 |
| EDIT Editas Medicine Inc. Common Stock | $283.93M | — | $2.35 | ▼ 3.69% | $1.66$4.33 |
| LCTX Lineage Cell Therapeutics Inc. Common Stock | $281.71M | — | $0.98 | ▼ 1.01% | $0.8823$2.09 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual MeetingYahoo · 9/24/2026
- PVG Asset Management Announces Plan for First 100 Days at Anavex Life SciencesYahoo · 9/18/2026
- Glass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management’s Call for ChangeYahoo · 9/17/2026
- Anavex Life Sciences Corp. (AVXL) Discusses Board Misalignment, Leadership Concerns, and Strategic Changes for Company Turnaround TranscriptSeekingAlpha · 9/16/2026
- PVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price UnderperformanceYahoo · 9/14/2026
- Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director NomineesYahoo · 9/14/2026
Insider Activity
Insider Actions →- Boenisch Sandra · September 24, 2026 · Grant25.0K
- Boenisch Sandra · September 24, 2026 · Grant20.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 40.36M
- Total value held
- $121.08M
- Institutional holders
- 187
- Unknown7.61M
- Unknown4.51M
- Unknown3.86M
- Unknown3.25M
- Unknown2.19M
- Unknown1.54M
- Unknown1.17M
- Unknown940.5K
- Unknown863.1K
- Unknown804.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
AVXL Stockholders Elect All Director Nominees for 2026 Meeting
At the 2026 annual meeting, AVXL stockholders voted to elect all of the company's director nominees. The vote confirmed the current board composition and did not introduce any new directors. This routine corporate action is unlikely to change the company's strategic direction or operations in the short term.
AVXL Stockholders Elect All Director Nominees for 2026 Meeting. At the 2026 annual meeting, AVXL stockholders voted to elect all of the company's director nominees. The vote confirmed the current board composition and did not introduce any new directors. This routine corporate action is unlikely to change the company's strategic direction or operations in the short term.